Cancer diagnostics company Biomoda Inc (OTCBB: BMOD) declared on Tuesday that it has received a notice of allowance for a US Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilised in the company's screening assay for the early detection of cancer.   The US Patent entitled "Method for Making 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) Solution and Composition Comprising TCPP" describes the new formulation of the Biomoda assay trademarked under the name CyPath, the company said.   TCPP is the foundation for several Biomoda product lines and medical diagnostics.   In addition Biomoda is seeking approval from the US Food and Drug Administration (FDA) for its cytology-based screening technology as a Class III medical device. Multi-site Phase III trials, the final step before FDA approval, are scheduled to commence in early 2010.